Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma

D. A. Van Echo, S. Markus, J. Aisner, P. H. Wiernik

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Metastatic renal cell carcinoma is unresponsive to most chemotherapeutic agents employed to date including alkylating agents, antimetabolites, antibiotics, vinca alkaloids, and nitrosoureas. Progesterone derivatives or androgens give a low number of partial remissions and approximately a 20% subjective response rate. The current phase II study was undertaken to evaluate the therapeutic efficacy of a new investigational agent, 4' (9-acridinylamino)methanesulfon-m-anisidide (AMSA) in this disease.

Original languageEnglish (US)
Pages (from-to)1009-1010
Number of pages2
JournalCancer treatment reports
Volume64
Issue number8-9
StatePublished - 1980
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this